Restricted
Targeted or empiric therapy for gram positive infections including skin and soft tissue, and pneumonia when first line therapies are precluded by allergy, organism resistance or intolerance/adverse drug reaction.
Covers MRSA and VRE.
CBC at least once/week
Visual testing for therapy >3 months or if symptoms develop on therapy.
IV Administration: 600 mg premixed bags; infuse over 60 min (Premixed bags are not compatible with pumps used by Community IV Program)
NLPDP Status (PO): Special Authorization required
Antimicrobial class: Oxazolidinone
Pregnancy category: C
Average serum half life: 5 hours
CSF penetration: Therapeutic
Lung penetration: Therapeutic
Urine penetration: Therapeutic